ALT - Altimmune, Inc.
| Previous Close | 2.0100 |
| Open | 1.9800 |
| Bid | 1.9000 x 2900 |
| Ask | 1.9600 x 900 |
| Day's Range | 1.9000 - 1.9800 |
| 52 Week Range | 1.5100 - 5.9400 |
| Volume | 348,999 |
| Avg. Volume | 195,638 |
| Market Cap | 29.296M |
| Beta (5Y Monthly) | 2.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6900 |
| Earnings Date | Mar 29, 2020 - Apr 02, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 19, 2017 |
| 1y Target Est | 7.20 |
- GlobeNewswire
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor. In the study, three doses of ALT-702 were injected into one tumor mass over 5 days with concomitant treatment with an anti-CTLA4 antibody immune checkpoint inhibitor administered intraperitoneally. “These data represent a key milestone for the development of ALT-702 and are highly supportive of the immune-mediated antitumor activity of ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune.
- GlobeNewswire
Altimmune to Present at the 2020 NASH-TAG Conference
GAITHERSBURG, Md., Jan. 07, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Altimmune, Inc. (ALT)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
Altimmune to Host Key Opinion Leader Call on ALT-801 for the Treatment of NASH
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on ALT-801, the Company’s GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic steatohepatitis (NASH), on Thursday, December 5th at 11am Eastern Time. The call will feature a presentation by Stephen A. Harrison, MD (Pinnacle Clinical Research), a leading expert in the field of NASH, who will provide an overview of current and future treatment approaches for this disorder. Dr. Harrison will be available to answer questions at the conclusion of the call.
- GlobeNewswire
Altimmune Announces Third Quarter 2019 Financial Results and Provides a Business Update
GAITHERSBURG, Md., Nov. 13, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended September.
- Simply Wall St.
If You Had Bought Altimmune (NASDAQ:ALT) Stock A Year Ago, You'd Be Sitting On A 48% Loss, Today
It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...
- GlobeNewswire
Altimmune to Announce Third Quarter 2019 Financial Results on November 14
GAITHERSBURG, Md., Nov. 06, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating.
- Barrons.com
Why the Facebook political-ads debate could be a windfall for legacy media
Analyst: ‘FB has made clear they do not see themselves as having the authority to make such a decision, while Twitter has taken the other side’
- GlobeNewswire
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Oct. 10, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following.
- GlobeNewswire
Altimmune Appoints M. Scott Harris, M.D. as Chief Medical Officer
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker, who resigned June 30, 2019 to continue her professional focus on infectious diseases. “Dr. Harris is a seasoned medical professional with extensive experience in hepatology and gastroenterology and broad expertise in managing clinical trials from early stage development through successful Phase 3 trials.
- GlobeNewswire
Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an additional $3.7 million. The increase in funding is primarily directed toward a Phase 1b clinical trial of NasoShield to evaluate alternative methods of intranasal dosing in humans. In 2018, BARDA awarded Altimmune $2.5 million for further NasoShield development including a comparison of different methods of administration of the vaccine in preclinical models.
- GlobeNewswire
Altimmune Announces Second Quarter 2019 Financial Results and Provides a Business Update
GAITHERSBURG, Md., Aug. 13, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months.
- GlobeNewswire
Altimmune to Announce Second Quarter 2019 Financial Results on August 14
GAITHERSBURG, Md., Aug. 05, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating.
- GlobeNewswire
Altimmune Announces Closing of Acquisition of Spitfire Pharma, Inc.
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc., including the product candidate ALT-801, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). The number of shares to be issued was determined based on the average of the closing prices of the Company’s common stock as reported on the Nasdaq Global Market for the twenty consecutive trading days prior to and including July 8, 2019, the date the definitive agreement was signed. Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies.
- Benzinga
Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio
Altimmune (NASDAQ: ALT ) shares are trading higher after the company announced it will acquire Spitfire Pharma , which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio. ...
- GlobeNewswire
Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
Company to conduct conference call on Tuesday, July 9, 2019 at 8:30 a.m. GAITHERSBURG, Md., July 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH).
- GlobeNewswire
Altimmune Appoints Will Brown as Chief Financial Officer
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018. “Will has proven to be a valuable member of our senior leadership team since he stepped into the CFO role over a year ago,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer.
- GlobeNewswire
Altimmune Announces Successful Pre-IND Meeting with FDA
Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase 2 trial design and manufacturing plans for HepTcell. The FDA did not object to the planned study design and patient populations, as well as plans for manufacturing and product testing, and did not recommend any additional studies in preparation for an IND submission and initiation of Phase 2 trials. Altimmune intends to conduct a Phase 2 study in the United States and the pre-IND meeting was held to obtain feedback from the FDA on our intended development path.
- GlobeNewswire
Altimmune Announces Important Additions to its Patent Portfolio for HepTcell and ALT-702 Programs
Altimmune, Inc. (ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States. “We are pleased to strengthen our intellectual property protection with the additional patents covering our development candidates, HepTcell and ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. For HepTcell, the Company has been granted U.S. Patent No. 10,300,132 entitled “Vaccines Against Hepatitis B Virus.” The patent, which expires in 2035 accounting for 515 days of patent term adjustment, provides important additional IP protection for the HepTcell clinical development program, an immunotherapeutic being developed for patients chronically infected with the hepatitis B virus (“HBV”).
- GlobeNewswire
Altimmune Announces First Quarter 2019 Financial Results and Provides a Business Update
GAITHERSBURG, Md., May 14, 2019 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended.
